Literature DB >> 29562985

Rifampicin-resistant tuberculosis patients in Myanmar in 2016: how many are lost on the path to treatment?

K K K Htet1, K T Soe1, A M V Kumar2, S Saw1, H M Win Maung3, Z Myint4, T M M Khine4, S T Aung3.   

Abstract

SETTING: Regional tuberculosis (TB) centres of the Yangon and Mandalay Regions of Myanmar, which account for 65% of all notified rifampicin-resistant tuberculosis (RR-TB) cases countrywide.
OBJECTIVE: To determine 1) initial loss to follow-up (LTFU), 2) treatment delay, and 3) factors associated with initial LTFU and treatment delay among RR-TB patients residing in the Yangon and Mandalay regions diagnosed using Xpert® during January-August 2016.
DESIGN: This was a retrospective cohort study. Each diagnosed patient was tracked in the drug-resistant TB treatment registers of the Yangon and Mandalay regional treatment centres for January-December 2016 using patient name, age, sex, township and date of diagnosis. If the diagnosed patient was not found in the treatment register by 31 December 2016, he/she was considered 'initial LTFU'.
RESULTS: Of the 1037 RR-TB patients diagnosed, 310 (30%) experienced initial LTFU, which was significantly higher among patients aged 55 years and among those diagnosed in the Mandalay Region. A treatment delay of >1 month was observed in 440 (70%) patients (median delay 41 days). Delay was uniformly high across patient subgroups, and was not associated with any factor.
CONCLUSION: Initial LTFU and treatment delays among RR-TB patients were high. Future studies using qualitative research methods are needed to ascertain the reasons for this observation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29562985     DOI: 10.5588/ijtld.17.0452

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  4 in total

1.  The Growing Importance of Tuberculosis Preventive Therapy and How Research and Innovation Can Enhance Its Implementation on the Ground.

Authors:  Anthony D Harries; Ajay M V Kumar; Srinath Satyanarayana; Pruthu Thekkur; Yan Lin; Riitta A Dlodlo; Mohammed Khogali; Rony Zachariah
Journal:  Trop Med Infect Dis       Date:  2020-04-16

2.  Pre-treatment loss to follow-up and treatment delay among bacteriologically-confirmed tuberculosis patients diagnosed in Mandalay Region, Myanmar.

Authors:  Ko Ko Htwe; Nang Thu Thu Kyaw; Ajay M V Kumar; Khine Wut Yee Kyaw; Myo Minn Oo; Thandar Thwin; Saw Saw; Si Thu Aung
Journal:  Trop Med Health       Date:  2019-05-02

3.  Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012-2019: Are We on the Right Track?

Authors:  Sharofiddin Yuldashev; Nargiza Parpieva; Salikhdjan Alimov; Laziz Turaev; Khasan Safaev; Kostyantyn Dumchev; Jamshid Gadoev; Oleksandr Korotych; Anthony D Harries
Journal:  Int J Environ Res Public Health       Date:  2021-04-28       Impact factor: 3.390

Review 4.  What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?

Authors:  Anthony D Harries; Yan Lin; Ajay M V Kumar; Srinath Satyanarayana; Kudakwashe C Takarinda; Riitta A Dlodlo; Rony Zachariah; Piero Olliaro
Journal:  F1000Res       Date:  2018-07-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.